STRATA Skin Sciences (NASDAQ:SSKN) Second Quarter 2025 Results
Key Financial Results
- Revenue: US$7.66m (down 9.2% from 2Q 2024).
- Net loss: US$2.49m (loss widened by US$2.39m from 2Q 2024).
- US$0.60 loss per share (further deteriorated from US$0.028 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
STRATA Skin Sciences Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 107%.
Looking ahead, revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 5.7% from a week ago.
Risk Analysis
Be aware that STRATA Skin Sciences is showing 2 warning signs in our investment analysis and 1 of those is significant...
Valuation is complex, but we're here to simplify it.
Discover if STRATA Skin Sciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.